Myriad can patent breast cancer genes: US court

July 30, 2011 by Kerry Sheridan

A federal appeals court on Friday ruled in favor of Myriad Genetics after a legal battle over whether the US company could keep its patent on genes linked to an inherited form of breast cancer.

The ruling overturns a lower court's decision and allows the Utah-based company to maintain its patents on the isolated , known as BRCA1 and BRCA2, despite complaints from rights groups who say it creates an unfair monopoly and limits women's health choices.

The US Court of Appeals for the Federal Circuit decided such patents on isolated could be held, in accordance with the "longstanding practice" of the (PTO), over the past 29 years.

The 2-1 court ruling also said the company cannot patent five broadly framed processes of comparing or analyzing because they were "abstract mental processes."

However, a Myriad spokeswoman said that aspect of the ruling did not hurt the company's ability to test for the isolated genes.

"Our intellectual property position today is no different than before the ACLU () even brought this case," Rebecca Chambers, head of investor relations, told AFP.

She said the company still has 232 method claims, or steps that explain exactly how to test, "as part of 23 patents which describe how we go about doing the BRAC analysis test that were not even part of this lawsuit."

Backed by pharmaceutical company Eli Lilly, Myriad obtained a series of US patents in the mid-1990s on two genes -- BRCA1 and BRCA2 -- strongly associated with hereditary forms of breast and ovarian cancer in women.

According to the , 12 percent of women in the general population will develop in their lifetimes, compared to 60 percent of women who have inherited a mutation in BRCA1 or BRCA2.

With ovarian cancer, 1.4 percent of women may be diagnosed in their lifetimes but the number rises to 15-40 percent of women with the BRCA1 or BRCA2 mutation.

The patents held by Myriad mean the company owns the "exclusive right to perform diagnostic tests on the BRCA1 and BRCA2 genes and to prevent any researcher from even looking at the genes without first getting permission from Myriad," the ACLU said in a statement.

A key complaint in the lawsuit, was filed in 2009 by a coalition of patient advocacy and medical groups represented by the ACLU, was that the company wielded too much control over the tests and costs.

"Myriad's monopoly on the BRCA genes makes it impossible for women to access alternate tests or get a comprehensive second opinion about their results. It also allows Myriad to charge a high price for its tests," ACLU lawyer Sandra Park told AFP.

The ACLU was consulting with its clients and would make a decision soon about whether to appeal to the full 12-member court of appeals for the federal circuit or to bring the matter before the Supreme Court, she said.

Analyst Robert Cook-Deegan of the Institute for Genome Sciences and Policy at Duke University in North Carolina, said he expected the legal battle would continue over whether human DNA is something that can be patented and owned.

"This is probably not the last stage in this game," he said. "The fact that all three judges have given very different lines of reasoning does suggest to me that there is going to be another round to go here."

If the matter reaches the Supreme Court, he said the outcome would be "very unpredictable."

But Friday's ruling was expected to make few waves in the biotech industry or on the US stock market.

"The impact of the federal circuit decision in the Myriad case on the biotech industry should be minimal," said biotech intellectual property lawyer Roberte Marie Makowski.

"At least for now, this decision provides a level of certainty for the industry's existing patents and research endeavors."

Biotech companies first began patenting genes and genetic material in the 1980s. More than 20 percent of the 24,000 human gene patents granted since then have been in the United States.

A gene inside the human body cannot be patented. But once it is identified, removed and isolated, a company can apply for exclusive rights to exploit it for commercial purposes.

Only a handful of countries -- including Brazil and Chile -- do not allow patents on genes in any form.

Related Stories

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Scientists block the siren call of two aggressive cancers

January 23, 2018
Aggressive cancers like glioblastoma and metastatic breast cancer have in common a siren call that beckons the bone marrow to send along whatever the tumors need to survive and thrive.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

nanotech_republika_pl
5 / 5 (1) Jul 30, 2011
Does that mean that when somebody will have their _full_ genome scanned, they will have the results presented to them with Swiss cheese holes, the patented gene holes? Because if they do have the full info then there always be the info available on Internet to interpret the patent genes. I don't need a doctor's 2nd opinion to interpret the data if it is a standard algorithm.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.